Jin-Ji Yang

10.0k total citations · 2 hit papers
12 papers, 7.6k citations indexed

About

Jin-Ji Yang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Jin-Ji Yang has authored 12 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Jin-Ji Yang's work include Lung Cancer Treatments and Mutations (11 papers), Cancer Genomics and Diagnostics (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). Jin-Ji Yang is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Cancer Genomics and Diagnostics (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). Jin-Ji Yang collaborates with scholars based in China, Hong Kong and Taiwan. Jin-Ji Yang's co-authors include Tony Mok, Yi‐Long Wu, James Chih‐Hsin Yang, Haiyi Jiang, Nagahiro Saijo, Sumitra Thongprasert, Masahiro Fukuoka, Emma Duffield, Claire Watkins and Yutaka Nishiwaki and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Jin-Ji Yang

12 papers receiving 7.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

2009 6.4k citations Tony Mok, Yi‐Long Wu et al. New England Journal of Medicine profile →
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer

2018 225 citations Yi‐Long Wu, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Jin-Ji Yang

Since Specialization

Citations

This map shows the geographic impact of Jin-Ji Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jin-Ji Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jin-Ji Yang more than expected).

Fields of papers citing papers by Jin-Ji Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jin-Ji Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jin-Ji Yang. The network helps show where Jin-Ji Yang may publish in the future.

Co-authorship network of co-authors of Jin-Ji Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Jin-Ji Yang. A scholar is included among the top collaborators of Jin-Ji Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jin-Ji Yang. Jin-Ji Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen 2024 ·Lung Cancer ·(unknown), (unknown), (unknown), Tao Jiang, (unknown), (unknown), Qing Zhou, Xuchao Zhang, Zheng Zheng, Shiyuan Chen, Xue Zheng, Hongbo Zheng, Beibei Mao, Longlong Gong, Xianwen Chen, Wendy Wu, (unknown), (unknown), Jin-Ji Yang	4
2	Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study 2019 ·The Lancet Respiratory Medicine ·Caicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana, Jianying Zhou, Yiping Zhang, Jianxing He, Jin-Ji Yang, Ying Cheng, Se‐Hoon Lee, Lilian Bu, Tingting Xu, Li Yang, Chao Wang, Ting Liu, Peter N. Morcos, You Lu, Li Zhang	186
3	Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma 2019 ·Journal of Thoracic Oncology ·Chao Zhang, Jianjun Zhang, (unknown), (unknown), Zhi Xie, Jian Su, Song Dong, Qiang Nie, Yang Shao, Qing Zhou, Jin-Ji Yang, Xue-Ning Yang, Xu‐Chao Zhang, Zhi Li, Yi‐Long Wu, Wen‐Zhao Zhong	127
4	Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer breakdown → 2018 ·Journal of Clinical Oncology ·Yi‐Long Wu, James Chih‐Hsin Yang, Dong‐Wan Kim, Shun Lü, Jianying Zhou, Takashi Seto, Jin-Ji Yang, Noboru Yamamoto, Myung‐Ju Ahn, Toshiaki Takahashi, Takeharu Yamanaka, (unknown), Debasish Roychowdhury, Jolanda Paolini, Tiziana Usari, Keith D. Wilner, Kōichi Goto	225
5	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial 2015 ·The Lancet Oncology ·Jean‐Charles Soria, Yi‐Long Wu, Kazuhiko Nakagawa, Sang-We Kim, Jin-Ji Yang, Myung‐Ju Ahn, Jie Wang, James Chih‐Hsin Yang, You Lü, Shinji Atagi, Santiago Ponce, Dae Ho Lee, Yunpeng Liu, Kiyotaka Yoh, Jianying Zhou, Xiaojin Shi, Alan Webster, Haiyi Jiang, Tony Mok	309
6	Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation 2014 ·Clinical Cancer Research ·Jin-Ji Yang, Xu‐Chao Zhang, Jian Su, Chong‐Rui Xu, Qing Zhou, (unknown), Zhi Xie, (unknown), (unknown), Ben‐Yuan Jiang, Zhen Wang, (unknown), Xue-Ning Yang, Wen‐Zhao Zhong, Qiang Nie, (unknown), Tony Mok, Yi‐Long Wu	135
7	A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805) 2014 ·Lung Cancer ·Qing Zhou, (unknown), (unknown), Ying Cheng, Cheng Huang, Li Zhang, Chong‐Rui Xu, (unknown), (unknown), Jian Su, Xu‐Chao Zhang, Jin-Ji Yang, Yi‐Long Wu	16
8	Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study 2013 ·Lung Cancer ·Yi‐Long Wu, Masahiro Fukuoka, Tony Mok, Nagahiro Saijo, Sumitra Thongprasert, James Chih‐Hsin Yang, (unknown), Jin-Ji Yang, Yuri Rukazenkov	41
9	Treating Patients With EGFR-Sensitizing Mutations: First Line or Second Line—Is There a Difference? 2013 ·Journal of Clinical Oncology ·Tony Mok, Jin-Ji Yang, (unknown)	90
10	EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas 2012 ·The Oncologist ·Zhiyong Chen, Wen‐Zhao Zhong, Xu‐Chao Zhang, Jian Su, Xue-Ning Yang, Zhi Hong Chen, Jin-Ji Yang, Qing Zhou, (unknown), She-Juan An, (unknown), Ben‐Yuan Jiang, Tony Mok, Yi‐Long Wu	133
11	Genetic Evolution of Epidermal Growth Factor Receptor in Adenocarcinoma With a Bronchioloalveolar Carcinoma Component 2010 ·Clinical Lung Cancer ·Wen‐Zhao Zhong, Yi‐Long Wu, Xue-Ning Yang, Ailin Guo, Jian Su, Xu‐Chao Zhang, Donglan Luo, Zhen Wang, (unknown), Qing Zhou, Chong‐Rui Xu, Guibin Qiao, (unknown), Jin-Ji Yang, Tony Mok	7
12	Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma breakdown → 2009 ·New England Journal of Medicine ·Tony Mok, Yi‐Long Wu, Sumitra Thongprasert, James Chih‐Hsin Yang, (unknown), Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose, Yutaka Nishiwaki, Yuichiro Ohe, Jin-Ji Yang, Busyamas Chewaskulyong, Haiyi Jiang, Emma Duffield, Claire Watkins, Alison Armour, Masahiro Fukuoka	6355

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact